ONYX Pharmaceuticals Inc (ONXX)

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. The company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals Inc., develops and markets Nexavar tablet, a multiple kinase inhibitor for the treatment of liver cancer and advanced kidney cancer; and Stivarga tablets to treat metastatic colorectal cancer. It is also conducting Phase III clinical trial on Nexavar for the treatment of liver, kidney, thyroid, breast, and non-small cell lung cancers; and completed Phase III clinical trials on Stivarga to treat gastro intestinal stromal tumor. In addition, the company is developing Kyprolis, a proteasome inhibitor in Phase III and Phase I/II clinical trials to treat multiple myeloma; Phase II clinical trials to treat solid tumor; and Phase I clinical trials to treat hematologic malignancies, as well as provides research and development services to Palbociclib, a cell cycle kinase inhibitor in Phase II clinical trials to restore control in the misregulated cell cycle in tumor cells. Further, it offers Oprozomib, an oral proteasome inhibitor in Phase Ib/II clinical trials to treat patients with hematologic malignancies; ONX 0914, an inhibitor of the immunoproteasome in preclinical stage; and ONX 0801, a novel targeted oncology compound in Phase I clinical trials to combine two proven approaches to improve outcomes for cancer patients. The company was formerly known as Onyx Pharmaceuticals Merger Corporation and change its name to Onyx Pharmaceuticals, Inc. in May 1996. Onyx Pharmaceuticals, Inc. was founded in 1992 and is headquartered in South San Francisco, California. Onyx Pharmaceuticals, Inc. operates as a subsidiary of Amgen Inc.